4//SEC Filing
Trehu Elizabeth 4
Accession 0001640455-21-000072
CIK 0001640455other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 8:22 PM ET
Size
19.0 KB
Accession
0001640455-21-000072
Insider Transaction Report
Form 4
Trehu Elizabeth
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-29$4.02/sh+5,100$20,502→ 98,685 total - Exercise/Conversion
Common Stock
2021-03-30$4.02/sh+100$402→ 93,685 total - Sale
Common Stock
2021-03-30$10.00/sh−100$1,000→ 93,585 total - Sale
Common Stock
2021-03-29$10.09/sh−5,100$51,459→ 93,585 total - Exercise/Conversion
Common Stock
2021-03-31$4.02/sh+8,300$33,366→ 101,885 total - Sale
Common Stock
2021-03-31$10.09/sh−8,300$83,747→ 93,585 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-30−100→ 212,185 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (100 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-31−8,300→ 203,885 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (8,300 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-29−5,100→ 212,285 totalExercise: $4.02Exp: 2025-11-12→ Common Stock (5,100 underlying)
Footnotes (4)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020. The Reporting Person exercised no discretion with respect to these transactions.
- [F2]Represents the weighted average share price of an aggregate total of 5,100 shares sold in the price range of $10.00 to $10.30 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Represents the weighted average share price of an aggregate total of 8,300 shares sold in the price range of $10.00 to $10.21 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]25% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and became exercisable in 12 quarterly installments thereafter.
Documents
Issuer
Jounce Therapeutics, Inc.
CIK 0001640455
Entity typeother
Related Parties
1- filerCIK 0001693456
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 8:22 PM ET
- Size
- 19.0 KB